All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matthias Holdhoff, Johns Hopkins University, discusses the treatment options for elderly patients with primary central nervous system (CNS) lymphoma.
Dr. Holdhoff explains how over 50% of patients who are diagnosed are 60 years or older. The outcomes for patients who are treated for primary central nervous lymphomas has significantly improved over the last 4 decades, partly due to more aggressive therapies that have been tolerated reasonably well. Dr. Holdhoff then goes on to explain how the term elderly has evolved over time, as patients tend to live longer and comorbidities can be better managed, as well as how giving therapy with high dose methotrexate can very well be tolerated in old or very old patients.
What should be done for elderly patients with primary central nervous system lymphoma?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Bendamustine plus ofatumumab for naïve, elderly patients with DLBCL: Results from a phase II trial
This trial investigated the efficacy of bendamustine and ofatumumab in elderly patients with newly-diagnosed DLBCL, who were not good candidates for...
Real-world outcomes of very elderly lymphoma patients in Sweden
The results of this real-world analysis in Swedish very elderly lymphoma patients, indicate that in DLBCL and MZL current active treatments offer a significantly superior survival...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox